Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 6Myeloid 4Sarcoma 2Plasma cell 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Mastocytosis 4Pruritus 2Piebaldism 2Mastocytosis, Systemic 2Blushing 2

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × masitinib × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00831974 2018-12-11

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

AB Science

Phase 2 Completed
23 enrolled
Myeloid

Mastocytosis

NCT01266369 2018-12-10

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

AB Science

Phase 2 Completed
21 enrolled
Myeloid

Mastocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡